Adm Tronics Stock Price, News & Analysis

ADMT announced positive results from a study by North Carolina State University on its Calmer Canine device, effective in treating canine separation anxiety (CSA). The double-blind, placebo-controlled study showed that two-thirds of treated dogs had a 100% improvement in resting behavior after four weeks. Approximately 13 million dogs in the US suffer from CSA, highlighting the potential market impact of this non-invasive therapy. Calmer Canine is manufactured at ADMT's facility in NJ, signaling strong manufacturing capabilities and market readiness.

ADM Tronics Unlimited, Inc. (OTCQB: ADMT) announced its financial results for the second fiscal quarter ended September 30, 2021. Revenues totaled $851,859, an 8% decrease from the previous year, primarily due to supply chain challenges impacting their electronics and chemical segments. However, revenues for the first six months increased by 5% to $1,573,217. The company reported a loss from operations of $552,574, significantly down from a profit of $5,366 last year, impacted by non-cash expenses and increased allowances for doubtful accounts.

ADM Tronics Unlimited (ADMT) has signed a five-year marketing and distribution agreement with SBLP Capital for its Vet-Sonotron veterinary therapy device. This device targets equine and small animal markets in key countries, including the U.S., Canada, and several European nations. The agreement, which can be renewed for another five years, is based on minimum sales requirements. Positive feedback on pre-production units suggests strong market potential. The Vet-Sonotron treats musculoskeletal pain using pulsed radio frequency therapy, enhancing ADMT's product portfolio.

ADM Tronics Unlimited, Inc. (OTCQB - ADMT) has announced the completion of its new Vet-Sonotron® device, designed for treating musculoskeletal pain and inflammation in animals. The device utilizes pulsed radio frequency therapy (PRFT) and is aimed at small and large animals, including thoroughbreds and dressage horses. Following pre-production evaluations, the company plans to commercialize the Vet-Sonotron, anticipating significant benefits in animal therapy. Additionally, the company provides manufacturing and regulatory services at its FDA-registered facility in Northvale, NJ.

ADM Tronics Unlimited, Inc. (OTCQB - ADMT) won First Place in Electronics at the Go Global Awards on October 14, 2021. This accolade recognizes the company’s innovation and leadership in electronic medical device development. Competing against 6,416 entries from 178 countries, ADMT's President, Andre DiMino, expressed gratitude for the honor, emphasizing the company’s commitment to quality in electronic technologies. The Go Global Awards celebrate organizations that contribute to the global economy through innovative strategies.

ADM Tronics Unlimited (OTCQB - ADMT) has been selected by Intubation Science, Inc. to finalize the engineering and manufacturing of the Light Speed Intubator-Imaging Stylet System. This innovative, single-use intubation device aims to enhance airway visualization and improve patient safety during intubation procedures.

The system is designed for hospital use and emergency responders, particularly during the COVID-19 pandemic. ADMT will also ensure regulatory compliance for volume production at its FDA-Registered facility in Northvale, NJ.

ADM Tronics Unlimited (OTCQB:ADMT) reported improved financial results for the first fiscal quarter ended June 30, 2021. Revenues rose by over 26% to $721,358 compared to $569,093 in the previous year, attributed to customer activity resuming post-COVID-19 disruptions. Engineering services saw revenue growth of 94% to $183,527, while the chemical segment grew 69% to $315,257. However, the electronics manufacturing segment faced a 23% decline due to raw material shortages. Net loss decreased by 73% to $30,672 from $115,736 in Q1 2020.

ADM Tronics Unlimited, Inc. (OTCQB:ADMT) reported its fiscal year results for the year ending March 31, 2021, highlighting the impact of the COVID-19 pandemic on operations. The company experienced an 11% decline in revenues, totaling $3,090,631, compared to $3,485,992 the previous year. Operating expenses rose to $1,842,320 from $1,617,409. Loss from operations was $680,478, increasing from $43,389. Despite challenges, ADMT increased its R&D investments and is exploring partnerships for future commercialization of its medical device technologies.

ADM Tronics Unlimited, Inc. (ADMT) announced its participation in the Lytham Partners Summer 2021 Investor Conference, scheduled from June 14 to June 16, 2021. President Andre DiMino will be available for virtual one-on-one meetings during the event, where he aims to discuss the company's activities and developments. ADMT specializes in designing, developing, and manufacturing electronic medical devices at its FDA-Registered and ISO-Certified facility in Northvale, NJ, with a unique capability to handle all phases of medical device development in-house.